Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors (DUET-4)
Enrolling By Invitation
18-99 years
All
Phase
1
1 participants needed
1 Location
Brief description of study
This is a Phase 1, multiple-dose, ascending dose-escalation and expansion study of XmAb22841, both as a monotherapy and in combination with pembrolizumab. The study is designed in 2 parts, Part A and Part B. Part A is a 3 + 3 dose escalation designed to assess both XmAb22841 administered as a single agent as well as in combination with pembrolizumab. Part B will assess the MTD/RD determined in Part A.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: solid tumors
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male or Female Age 18 or older Adequate archival tumor
Updated on
01 Aug 2024.
Study ID: 833002
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com